Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of the ARASENS study, which is a phase 3 trial on the use of darolutamide for men with metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract #TPS5092: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Advertisement